Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea

被引:625
作者
Kyne, L [1 ]
Warny, M
Qamar, A
Kelly, CP
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Gerontol Div, Boston, MA 02215 USA
[2] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Boston, MA 02215 USA
关键词
D O I
10.1016/S0140-6736(00)03592-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background We have reported that symptom-free carriers of Clostridium difficile have a systemic anamnestic immune response to toxin A. The aim of this study was to determine whether an acquired immune response to toxin A, during an episode of C difficile diarrhoea, influences risk of recurrence. Methods We prospectively studied 63 patients with nosocomial C difficile diarrhoea. Serial serum IgA, IgG, and IgM concentrations against C difficile toxin A, toxin B, or non-toxin antigens were measured by ELISA. Individuals were followed for 60 days. Findings 19 patients died (30%). Of the 44 who survived, 22 had recurrent C difficile diarrhoea. Patients with a single episode of C difficile diarrhoea (n=22) had higher concentrations of serum IgM against toxin A on day 3 of their first episode of diarrhoea than those with recurrent diarrhoea (n=22, p=0.004). On day 12, serum IgG values against toxin A were higher in patients who had a single episode of diarrhoea (n=7) than in those who subsequently had recurrent diarrhoea (n=9, p=0.009). The odds ratio for recurrence associated with a low concentration of serum IgG against toxin A. measured 12 days after onset of C difficile diarrhoea, was 48.0 (95% CI 3.5-663). Interpretation A serum antibody response to toxin A, during an initial episode of C difficile diarrhoea, is associated with protection against recurrence.
引用
收藏
页码:189 / 193
页数:5
相关论文
共 28 条
[11]   CLOSTRIDIUM-DIFFICILE COLITIS [J].
KELLY, CP ;
POTHOULAKIS, C ;
LAMONT, JT .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (04) :257-262
[12]   Immune response to Clostridium difficile infection [J].
Kelly, CP .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1996, 8 (11) :1048-1053
[13]   HUMAN COLONIC ASPIRATES CONTAINING IMMUNOGLOBULIN-A ANTIBODY TO CLOSTRIDIUM DIFFICILE TOXIN-A INHIBIT TOXIN-A-RECEPTOR BINDING [J].
KELLY, CP ;
POTHOULAKIS, C ;
ORELLANA, J ;
LAMONT, JT .
GASTROENTEROLOGY, 1992, 102 (01) :35-40
[14]   Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. [J].
Kyne, L ;
Warny, M ;
Qamar, A ;
Kelly, CP .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (06) :390-397
[15]   Prospects for a vaccine for Clostridium difficile [J].
Kyne, L ;
Kelly, CP .
BIODRUGS, 1998, 10 (03) :173-181
[16]   TREATMENT WITH INTRAVENOUSLY ADMINISTERED GAMMA-GLOBULIN OF CHRONIC RELAPSING COLITIS INDUCED BY CLOSTRIDIUM-DIFFICILE TOXIN [J].
LEUNG, DYM ;
KELLY, CP ;
BOGUNIEWICZ, M ;
POTHOULAKIS, C ;
LAMONT, JT ;
FLORES, A .
JOURNAL OF PEDIATRICS, 1991, 118 (04) :633-637
[17]   Recurrent Clostridium difficile disease:: Epidemiology and clinical characteristics [J].
McFarland, LV ;
Surawicz, CM ;
Rubin, M ;
Fekety, R ;
Elmer, GW ;
Greenberg, RN .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1999, 20 (01) :43-50
[18]   NOSOCOMIAL ACQUISITION OF CLOSTRIDIUM-DIFFICILE INFECTION [J].
MCFARLAND, LV ;
MULLIGAN, ME ;
KWOK, RYY ;
STAMM, WE .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (04) :204-210
[19]  
Nair S, 1998, AM J GASTROENTEROL, V93, P1873
[20]  
OLSON MM, 1994, INFECT CONT HOSP EP, V15, P371